November 9th, 2018
DeCell Technologies Inc. and RegenMed—Ontario’s Premiere Tissue Bank—have signed partnership agreements to manufacture DermGEN™ for both domestic and international sales. RegenMed will both manufacture and distribute DermGEN™ in Canada while also manufacturing DermGEN™ for the International markets. In a separate deal, DeCell has partnered with Impactful Health Solutions (IHS) out of New Jersey, U.S.A., to begin sales of DermGEN™ in markets located in the Middle East. These agreements allow DermGEN™ to enter the healthcare market place so that clinicians can have an advanced, cost effective solution to treat chronic and acute wounds.